Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 7/20 | 0.59 |
| ▸ | DBF4 | Q9UBU7 | 7/20 | 0.59 |
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ZAP70 | P43403 | 4/20 | 0.42 |
| ▸ | SYK | P43405 | 4/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4387753 | 0.89 | CDC7 (0.62) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL4395196 | 0.85 | CDC7 (0.41) | CDC7DBF4ZAP70SYKSRC | |
| SCHEMBL4391924 | 0.85 | SYK (0.43) | CDC7DBF4ZAP70SYKSRC | |
| SCHEMBL4384008 | 0.82 | SYK (0.48) | ZAP70SYKSRCCDK2 | |
| SCHEMBL4387241 | 0.81 | LMNA (0.55) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL4385552 | 0.80 | SYK (0.50) | MAPTKDM4EKMT2AZAP70SYK | |
| SCHEMBL4388111 | 0.76 | SYK (0.54) | ZAP70SYKSRCCDK2 | |
| SCHEMBL5227039 | 0.76 | SYK (0.54) | ZAP70SYKSRCCDK2 | |
| SCHEMBL14216051 | 0.75 | ZAP70 (0.67) | CDC7DBF4MAPTKDM4ELMNA | |
| SCHEMBL4397546 | 0.75 | CDK2 (0.50) | ZAP70SYKSRCCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318954-A1 | Compounds | CYCLACEL LIMITED (GB) | 2008-12-25 | — | — | US | claimed |
| CN-1914199-A | Pyridyl or pyrimidyl thiazole compounds having protein kinase inhibitory activity | CYCLACEL LTD (GB) | 2007-02-14 | — | — | CN | claimed |
| EP-1751146-B1 | PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY | CYCLACEL LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| EP-1751146-B1 | PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY | CYCLACEL LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-20080318954-A1 | Compounds | CYCLACEL LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080318954-A1 | Compounds | CYCLACEL LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080318954-A1 | Compounds | CYCLACEL LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| EP-1751146-A2 | PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY | Cyclacel Limited (GB) | 2007-02-14 | — | — | EP | disclosed |
| CN-1914199-A | Pyridyl or pyrimidyl thiazole compounds having protein kinase inhibitory activity | CYCLACEL LTD (GB) | 2007-02-14 | — | — | CN | disclosed |
| WO-2005075468-A2 | PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY | CYCLACEL LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005075468-A2 | PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY | CYCLACEL LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318954-A1 | Compounds | CBR3, NR3C2, NR5A1 | CDC7 1258/4885DBF4 1294/4885TRPM8 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.